Pharma Focus Asia

GenScript Doubles Manufacturing Capacity for cGMP sgRNA and Non-Viral DNA Payloads in Jiangsu, China

Introduction:
GenScript enhances cGMP Manufacturing Capacity for sgRNA and Non-Viral DNA Payloads capacity. The facility will be loacted in Jiangsu, China.

Features:
The new state-of-the-art facility provides gene therapy startups a quick way to access top-notch materials. 

The recent expansion in Zhenjiang has introduced an additional 400,000 square feet of cGMP manufacturing space, creating room for growth and innovation.

As the field grows rapidly, there is an urgent need for non-viral GMP reagents. These materials help to move their new treatments from the early research stage to testing in people and eventually making them available for patients in less time than before.

This expansion includes the incorporation of four new production lines that are designed to cater to the growing demand for essential components in gene and cell therapies. 

These cutting-edge production lines have the capability to efficiently produce significant amounts of sgRNA, ssDNA, or dsDNA per batch.

The primary focus is to maintain superior purity levels is crucial in ensuring the safety and effectiveness of the therapies being developed.

Specifications:

Name  GenScript
Type  Expansion

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference